sur ALT5 Sigma Corp
Alyea Therapeutics to Participate in Key Events at 43rd J.P. Morgan Healthcare Conference
Alyea Therapeutics Corporation, a subsidiary of Alt 5 Sigma Corporation, will engage in prominent events during the J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. The focus will be on their lead asset, JAN123, a novel Low Dose Naltrexone (LDN) for non-addictive pain management, which is preparing for a pivotal Phase III study after receiving Orphan Drug designation.
Dr. Amol Soin, CEO of Alyea, is set to present at the Biotech Showcase and RESI JPM IPC as a finalist. Along with ALT5 Sigma CEO Peter Tassiopoulos, he will attend the Nasdaq Opening Bell Ceremony. They will also conduct one-on-one meetings to discuss regulatory pathways and the pre-clinical Clear Patch medication delivery platform.
In 2025, ALT 5 Sigma plans to spin off its healthcare assets into Alyea to focus on specialized business needs.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ALT5 Sigma Corp